Literature DB >> 24041208

Environmental monitoring for Aspergillus fumigatus in association with an immunosuppressed rabbit model of pulmonary aspergillosis.

Kimberly A Such1, Vidmantas Petraitis, Ruta Petraitiene, Gittel E Strauss, Patriss-Wais Moradi, Thomas J Walsh.   

Abstract

Aspergillus fumigatus causes life-threatening pneumonia in immunocompromised patients. Conidia, the infectious form of the organism, are handled in a biologic safety cabinet under BSL2 conditions. However because germinated conidia form noninfectious hyphae in tissue, we hypothesized that rabbits inoculated intratracheally would grow A. fumigatus in their lungs but that the environment would remain free of this fungus, potentially permitting maintenance of infected animals under ABSL1 conditions. We performed a surveillance study for the presence of A. fumigatus in the environment before proceeding with antifungal therapy studies of experimental pulmonary aspergillosis. The expected outcome included absence of A. fumigatus in the environment, stool, and blood and presence in rabbit lungs. Female SPF New Zealand white rabbits were immunosuppressed and inoculated intratracheally (n = 4) or intraesophageally (n = 2) with 1.25 × 10(8) conidia of A. fumigatus. Feces, pan liners, and walls were sampled daily during the 11-d experiment, and blood was sampled on days 2, 6, and 8 after inoculation. Samples were cultured on 5% Sabouraud glucose agar plates. Lungs were weighed and scored for hemorrhagic infarcts and homogenized for culture on 5% Sabouraud glucose agar and trypticase soy agar plates. Blood cultures, rabbit stool, and environmental swabs were all negative for A. fumigatus whereas the lungs inoculated intratracheally demonstrated 4.5 × 10(2) ± 0.8 × 10(2) CFU/g of A. fumigatus. Therefore, neutropenic rabbits with experimental invasive pulmonary aspergillosis do not shed conidia of A. fumigatus and can be safely housed under ABSL1 conditions after inoculation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24041208      PMCID: PMC3784658     

Source DB:  PubMed          Journal:  J Am Assoc Lab Anim Sci        ISSN: 1559-6109            Impact factor:   1.232


  25 in total

1.  Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Alia A Sarafandi; Amy M Kelaher; Caron A Lyman; Heather E Casler; Tin Sein; Andreas H Groll; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  J Infect Dis       Date:  2003-06-04       Impact factor: 5.226

2.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Cluster of cases of invasive aspergillosis in a transplant intensive care unit: evidence of person-to-person airborne transmission.

Authors:  David A Pegues; Brent A Lasker; Michael M McNeil; Patricia M Hamm; Judy L Lundal; Bernard M Kubak
Journal:  Clin Infect Dis       Date:  2001-12-19       Impact factor: 9.079

4.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.

Authors:  T J Walsh; J Bacher; P A Pizzo
Journal:  Lab Anim Sci       Date:  1988-08

5.  Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

Authors:  P Francis; J W Lee; A Hoffman; J Peter; A Francesconi; J Bacher; J Shelhamer; P A Pizzo; T J Walsh
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

Review 6.  The pathobiology of Aspergillus fumigatus.

Authors:  J P Latgé
Journal:  Trends Microbiol       Date:  2001-08       Impact factor: 17.079

7.  Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis.

Authors:  Thomas J Walsh; Mark C Wissel; Kevin J Grantham; Ruta Petraitiene; Vidmantas Petraitis; Miki Kasai; Andrea Francesconi; Margaret P Cotton; Johanna E Hughes; Lora Greene; John D Bacher; Pradip Manna; Martin Salomoni; Steven B Kleiboeker; Sushruth K Reddy
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

8.  Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.

Authors:  T F Patterson; W R Kirkpatrick; M White; J W Hiemenz; J R Wingard; B Dupont; M G Rinaldi; D A Stevens; J R Graybill
Journal:  Medicine (Baltimore)       Date:  2000-07       Impact factor: 1.889

9.  Fungal infections in cancer patients: an international autopsy survey.

Authors:  G Bodey; B Bueltmann; W Duguid; D Gibbs; H Hanak; M Hotchi; G Mall; P Martino; F Meunier; S Milliken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

10.  Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy.

Authors:  T J Walsh; K Garrett; E Feurerstein; M Girton; M Allende; J Bacher; A Francesconi; R Schaufele; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.